期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三唑类抗真菌药的研究新进展 被引量：6

New Research Progress of Triazole Anti-fungal Agents
下载PDF
导出
摘要 近年来三唑类抗真菌药发展很快,有多个广谱、低毒、高效的新化合物进入临床研究。综述了三唑类抗真菌药的最新研究进展,介绍了伏立康唑、泊沙康唑、ravaconazole 3个新药物,与其他抗真菌药比较,均显示了其优点。 Triazole anti- fungal agents have got rapid development in recent years. Many new chemical compounds with broad- spectrum, low toxicity and high efficacy activities got into clinical research. This article summarizes the latest studies on progress of triazole anti- fungal agents and introduces three new drugs, i. e. voriconazole,posaconazole, ravaconazole. Compared with the other anti- fungal agents, they have peculiar advantages.
作者 蒋正立 朱萍 林建群
机构地区 浙江省台州医院
出处 《中国药业》 CAS 2008年第4期19-21,共3页 China Pharmaceuticals
关键词 三唑类抗真菌药 伏立康唑 泊沙康唑 进展 triazole anti - fungal voriconazole posaconazole, development
分类号 R978.5 [医药卫生—药品]
  • 相关文献

参考文献31

  • 1Meis JFGM, Verweij PE. Current management of fungal infections[J]. Drug, 2001,61 (Suppl 1 ): 13 - 25.
  • 2Arevalo MP, Carrillo - Munoz AJ, Salgado J, et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY - 303366) against yeast pathogens : a comparative study with M27- A microdilution method[J]. Antimicrob Chemother, 2003, 51:163 - 166.
  • 3Takakura S, Fujihara N, Saito T, et al. National surveillance of species distri- bution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin[J]. Antimicrob Chemother, 2004, 53:283 - 289.
  • 4Pfaller MA, Messer SA, Mills K, et al. Evaluation of Etest Method for Determining Posaconazole MICs for 314 Clinical Isolates of Candida Species [ J ]. J Clin Microbiol, 2001, 39:3952 - 3954.
  • 5Pfaller MA, Diekema DJ, Jones RN, et al. International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program[J]. J Clin Microbiol, 2001, 39:3254 - 3259.
  • 6Pfaller MA, Messer SA, Mills K, et al. Evaluation of Etest Method for Deter- mining Caspofungin ( MK - 0991 ) Susceptibilities of 726 Clinical Isolates of Candida Species[J]. J Clin Microbiol, 2001, 39:4387 -4389.
  • 7S Arikan, JH Rex. New agents for the treatment of systemic fungal infections -current status[J]. Expert Opin Emerg Drugs, 2002,7 ( 1 ): 3 - 32.
  • 8Durand ML, Kim IK, D' Amico DJ, et al. Successful treatment of Fusarium endophtha-lmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin[J]. AM J Ophthalmol, 2005, 140(3): 552 - 554.
  • 9F Schuster, C Moeher, I Schmid , et al. Successful antifungal combination therapy with voriconazole and caspofungin[J]. Pediatr Blood Cancer, 2005, 44 (7) : 682 - 685.
  • 10Walsh TJ, Pappas P, Winston D J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungall therapy in patients with neutropenia and persistent fever[J]. New England J Med , 2002,346:225 - 234.

同被引文献71

引证文献6

二级引证文献53

中国药业
2008年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部